Lantern Pharma Files S-1 for Resale of 2.24M Shares

Lantern Pharma Inc. (LTRN) has filed an S-1 registration statement with the SEC on June 12, 2026. This filing pertains to the potential resale of up to 2,242,719 shares of common stock, which are issuable upon the exercise of warrants previously issued in a private placement on May 14, 2026. The company, which utilizes an AI platform called RADR® for cancer therapy development, notes that it will not receive proceeds from these resales, except for potential cash received from warrant exercises. The filing also highlights the company's financial position as of March 31, 2026, with total assets of $7.2 million and working capital of $3.3 million, and acknowledges substantial doubt about its ability to continue as a going concern without additional funding.